Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03472807
Other study ID # 2017-A01833-50
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 13, 2019
Est. completion date August 13, 2025

Study information

Verified date November 2023
Source University Hospital, Angers
Contact Elsa BERARDI
Phone +33 2 41 35 61 79
Email elberardi@chu-angers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Other than high-dose radiation and previous chemotherapy, few strong risk factors have been identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers diagnosed during the paediatric period occur in children born with a genetic mutation, increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with congenital anomalies and specific genetic syndromes. Some germline genetic alterations are well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children with none of these mutations have clinical presentations that strongly suggest the involvement of a genetic predisposition. Comprehensive genetic testing for all such patients is an important factor for improving disease surveillance. Such opportunities are now available thanks to whole exome sequencing (WES). In oncology, an important clinical application of WES will be to routinely identify mutations associated with inherited cancer predispositions and to guide cancer risk-management decisions. Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours. The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.


Description:

-Primary objective : Our aim is to identify new mutations and genes involved in paediatric cancer predisposition associating developmental delay by WES of a sub-cohort of patients included in the TED database. -Secondary objectives : 1. Describe inherited predisposition to cancer. 2. Improve genetic counselling processes. 3. Initiate clinical exome sequencing in childhood cancer treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date August 13, 2025
Est. primary completion date February 13, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - For "Patient cancer" : - Child having developed a cancer combined with a delay of development and\or an intellectual deficiency before the age of 18 years and followed for a cancer of the child in one of hospital center of the Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent (SFCE) - At least a parent still alive and available to make genetic analyses - For "Parent of cancer patient" : - Parent whose child meets the criteria of inclusion of "Cancer patient" Exclusion Criteria: - For "Cancer patient" : - Genetic predisposition already identified at the child - Absence of histological confirmation - Child died without DNA of the available germinal lineage - For "Parent of cancer patient" : - Parent whose child doesn't meets the criteria of inclusion of "Cancer patient"

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Collection of blood sample or saliva
at Inclusion
Collection of a tumor sample taken before the participation of the patient in study
at Inclusion
Collection of blood sample if tumor sample is not available
at Inclusion

Locations

Country Name City State
France University Hospital of Amiens Amiens
France University Hospital of Angers Angers
France Cancer Center Bergonie Institut Bordeaux
France University Hospital of Bordeaux Bordeaux
France University Hospital of Brest Brest
France University Hospital of Clermont Ferrand Clermont-Ferrand
France University Hospital of Dijon Dijon
France University Hospital of Grenoble Grenoble
France University Hospital of Lille Lille
France University Hospital of Limoges Limoges
France Institut of Haematology and Paediatric Oncology of Lyon Lyon
France University Hospital of Marseille Marseille
France University Hospital of Montpellier Montpellier
France University Hospital of Nancy Nancy
France University Hospital of Nantes Nantes
France University Hospital of Nice Nice
France Institut Curie Paris
France University Hospital of Kremlin Bicetre Paris
France University Hospital of Necker Paris
France University Hospital of Trousseau Paris
France University Hospital of Rennes Rennes
France University Hospital of Rouen Rouen
France University Hospital of Saint Etienne Saint-Étienne
France University Hospital of Strasbourg Strasbourg
France University Hospital of Tours Tours
France Institut Gustave Roussy Villejuif
Réunion University Hospital of Saint Denis de La Reunion Saint-Denis

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Countries where clinical trial is conducted

France,  Réunion, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and type of germline and somatic genetic variants of pathological significance and associated with the disease. WES and RNA sequence data will be used to identify and characterise germline and somatic genetic variants of pathological significance and associated with the disease.
Descriptive statistics, such as counts and proportions of variants of pathological significance risk will be computed within each patient and family.
At inclusion
Secondary Related to secondary objectives (1) : Identification of biological pathways involved in childhood cancer predisposition. The deleterious mutations that the investigators will identify in genes related to childhood cancer predisposition will help to have a comprehensive framework of biological pathways involved in childhood cancer predisposition. At inclusion
Secondary Related to secondary objectives (2) : Overall success rate. Success is defined by the combined successes of quality interpretable genomic data are generated from sequencing tumor and germline tissues, and communicating genomic test results to the primary oncologist and the patient and his/her parents. At inclusion
Secondary Related to secondary objectives (3) : Number of clinical criteria justifying a WES. Descriptive statistics, such as counts and proportions of success by clinical presentation of the disease, by cancer types, by features of developmental delay, and, by class of age. At inclusion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT04313283 - Translating Peer-to-Peer Support Into a Clinical Setting N/A
Completed NCT05217186 - Associations Between Early Neonatal Neuroimaging, Hammersmith Infant Neurological Examination and General Movements
Completed NCT03599648 - The Pro-Parenting Study: Helping Parents Reduce Behavior Problems in Preschool Children With Developmental Delay N/A
Active, not recruiting NCT03625115 - The Opening Doors to Early Intervention Study N/A
Completed NCT02970565 - Family Nurture Intervention, A Group Model in Connecticut N/A
Recruiting NCT04026386 - A Center Based Early Intervention Program For Preschoolers With Developmental Disorders N/A
Completed NCT03561168 - Review of Diagnostic Yield of MRI Brain Results in Children Under Age 3 Years
Recruiting NCT05885113 - Developmental Intervention for Hospitalized Newborns With Congenital Heart Disease N/A
Completed NCT04562038 - Implementation of Electronic Shared Decision-Making Support for Early Intervention N/A
Active, not recruiting NCT05117827 - Pediatric Powered Wheelchair Standing Devices: An Exploratory Study N/A
Completed NCT05408351 - The Indonesian Version of Ages and Stages Questionnaire III Accuracy Compared to Bayley Scales of Infant Development III
Recruiting NCT05803252 - Videoconferencing-based Focused Acceptance and Commitment Therapy for Parents of SHCN Children N/A
Terminated NCT04398667 - European Non-interventional Study on Refractory Epilepsy With Developmental Delay
Completed NCT05778357 - The Effect of the Covid 19 Pandemic Process on the Neuromotor Developments of 6-24 Month-old Babies
Not yet recruiting NCT06412653 - Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders Phase 2
Completed NCT04048720 - Norwalk Feasibility Study N/A
Not yet recruiting NCT03209453 - Effects of Family Work Shop for Children With Developmental Delays: a Randomized Trial N/A
Recruiting NCT05751525 - Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome
Completed NCT03908268 - Children's Learning Centers Group FNI N/A